|
|
| | Ertugliflozin L-pyroglutamic acid Basic information |
| Product Name: | Ertugliflozin L-pyroglutamic acid | | Synonyms: | PF-04971729 L-pyroglutamic acid;Ertugliflozin L-pyroglutamic Acid (1:1);ERTUGLIFLOZIN PIDOLATE;Pidolate;PF-04971729 ((S)-5-oxopyrrolidine-2-carboxylic acid);(1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (1:1) compound with (S)-5-oxopyrrolidine-2-carboxylic acid;(S)-5-Oxopyrrolidine-2-carboxylic acid compound with (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (1:1);Gliadine L- pyroglutamate | | CAS: | 1210344-83-4 | | MF: | C27H32ClNO10 | | MW: | 566 | | EINECS: | | | Product Categories: | | | Mol File: | 1210344-83-4.mol |  |
| | Ertugliflozin L-pyroglutamic acid Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO: ≥ 125 mg/mL (220.85 mM) | | form | Solid | | color | White to off-white | | InChIKey | YHIUPZFKHZTLSH-NCRAORDPNA-N | | SMILES | C([C@@H]1CCC(=O)N1)(=O)O.O[C@@H]1[C@H]([C@H](O)[C@]2(CO)CO[C@@]1(C1C=CC(Cl)=C(CC3C=CC(OCC)=CC=3)C=1)O2)O |&1:1,10,11,12,14,19,r| |
| | Ertugliflozin L-pyroglutamic acid Usage And Synthesis |
| Description | Ertugliflozin L-pyroglutamic acid is a potent, selective, orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor with an IC50 value of 0.877 nM for h-SGLT2.It is the main active ingredient in the tablet ertugliflozin. It is the main active ingredient of ertugliflozin tablets. It is used as an adjunctive therapy for type 2 diabetes. | | Chemical Properties | Ertugliflozin L-pyroglutamic acid is a white to off-white powder, soluble in ethanol and acetone, slightly soluble in ethyl acetate and acetonitrile, and very slightly soluble in water. | | Uses | Ertugliflozin L-pyroglutamic Acid is a reagent in the synthesis of Ertugliflozin (1210344-57-2) a sodium/glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. | | Brand name | STEGLATRO | | in vivo | Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) reveals a concentration-dependent glucosuria after oral administration to rats[3]. | | IC 50 | SGLT2 |
| | Ertugliflozin L-pyroglutamic acid Preparation Products And Raw materials |
|